N-(2-氨基乙基)-n-甲基甲烷磺酰胺

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: N-(2-氨基乙基)-n-甲基甲烷磺酰胺
• 中文别名: N-(2-氨基乙基)-N-甲基甲烷磺酰胺盐酸盐
• 英文名称: N-(2-aminoethyl)-N-methylmethanesulfonamide hydrochloride
• 英文别名: 2-[methyl(methylsulfonyl)amino]ethanaminium chloride；2-[Methyl(methylsulfonyl)amino]ethanaminium chloride；2-[methyl(methylsulfonyl)amino]ethylazanium;chloride
• 化学式: C₄H₁₂N₂O₂S*ClH
• 分子量: 188.678
• InChiKey: XFDMJZRNRCNOOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.74
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)-n-甲基甲烷磺酰胺 、 1-benzyl-5-hydroxy-2-oxo-3-phenyl-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carboxylic acid methyl ester 在 sodium methylate 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 1-benzyl-5-hydroxy-2-oxo-3-phenyl-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carboxylic acid [2-(methanesulfonyl-methyl-amino)-ethyl]-amide
  参考文献：
  名称：

  [EN] NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
  [FR] DÉRIVÉS DE NAPHTHYRIDINE EN TANT QU'INHIBITEURS D'UN FACTEUR INDUCTIBLE PAR L'HYPOXIE

  摘要：

  本公开涉及能够抑制HIF羟化酶活性的新化合物、方法和组合物，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。

  公开号：

  WO2012106472A1

文献信息

• Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US07279487B2

  公开（公告）日：2007-10-09

  Hydroxynaphthyridinone carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein L, R1a, R1b, R1c, R2a, R2b, R3, R4, and R5 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  本文描述了式子所示的羟基萘啶酮羧酰胺类化合物，其为HIV整合酶的抑制剂和HIV复制的抑制剂，其中L、R1a、R1b、R1c、R2a、R2b、R3、R4和R5在此被定义。这些化合物对于预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病非常有用。这些化合物可作为化合物本身或以药用盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可以作为药物组合中的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。本文还描述了预防、治疗或延迟艾滋病发病的方法以及预防或治疗HIV感染的方法。
• NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
  申请人：Ng Danny

  公开号：US20140088101A1

  公开（公告）日：2014-03-27

  The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

  本公开涉及新型化合物、方法和组合物，能够抑制HIF羟化酶酶活性，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。
• Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
  申请人：Ng Danny

  公开号：US08921389B2

  公开（公告）日：2014-12-30

  The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

  本公开涉及新型化合物、方法和组合物，能够抑制HIF羟化酶酶活性，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。
• NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：ITEOS THERAPEUTICS

  公开号：US20150225367A1

  公开（公告）日：2015-08-13

  The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

  本发明涉及公式I的化合物或其药学上可接受的对映体、盐或溶剂。本发明还涉及将公式I的化合物用作TDO2抑制剂的用途。本发明还涉及将公式I的化合物用于治疗和/或预防癌症、神经退行性疾病，如帕金森病、阿尔茨海默病和亨廷顿病、慢性病毒感染，如丙型肝炎病毒和人类免疫缺陷病毒、抑郁症和肥胖症。本发明还涉及一种制造公式I的化合物的方法。
• SNAr or Sulfonylation? Chemoselective Amination of Halo(het)arene Sulfonyl Halides for Synthetic Applications and Ultralarge Compound Library Design
  作者：Vasyl Naumchyk、Vladyslav A. Andriashvili、Dmytro S. Radchenko、Dmytro Dudenko、Yurii S. Moroz、Andrey A. Tolmachev、Serhii Zhersh、Oleksandr O. Grygorenko

  DOI：10.1021/acs.joc.3c02636

  日期：2024.3.1

  The chemoselectivity of halo(het)arene sulfonyl halide aminations is studied thoroughly under parallel synthesis conditions, and the scope and limitations of the method are established. It is shown that SNAr-reactive sulfonyl halides typically undergo sulfonamide synthesis during the first step; the second amination is also possible provided that the SNAr-active center is sufficiently reactive. On

  在平行合成条件下深入研究了卤代（杂）芳烃磺酰卤胺化物的化学选择性，并确定了该方法的范围和局限性。结果表明， SN Ar反应性磺酰卤通常在第一步中进行磺酰胺合成；如果SN Ar活性中心具有足够的反应性，则第二次胺化也是可能的。相反，带有芳基化部分的磺酰氟在适当的控制下在后一个反应中心发生选择性转化。进一步的硫-氟化物交换（SuFEx）也是可能的，这对于某些磺酰卤类特别有价值。开发的两步并行双胺化方案提供了对 66.7 亿个化合物的合成可处理 REAL 型化学空间的访问（预期合成成功率 76%）。